Zealand Pharma A/S
ZEALDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
GlucaGen
Hypoglycemia
Glepaglutide
Short Bowel Syndrome
dasiglucagon
Hypoglycemia
Insulin Lispro
Diabetes Mellitus, Type 1
ZP4207
Hypoglycemia
ZP4207(dasiglucagon) glucagon analogue
Diabetes Mellitus Type 1
ZP1848
Short Bowel Syndrome
Petrelintide
Obesity
danegaptide
Focus of Study is STEMI
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
dasiglucagon | Phase 3 | Hypoglycemia | - | - |
Insulin Lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
ZP4207 | Phase 2 | Hypoglycemia | - | - |
ZP4207(dasiglucagon) glucagon analogue | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ZP1848 | Phase 2 | Short Bowel Syndrome | - | - |
Petrelintide | Phase 2 | Obesity | - | - |
danegaptide | Phase 2 | Focus of Study is STEMI | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Zealand Pharma A/S's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Zealand Pharma A/S's (ZEAL) pipeline across Phase 3, Phase 2. Its lead program is GlucaGen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zealand Pharma A/S's next FDA catalyst?→
Zealand Pharma A/S's (ZEAL) next tracked catalyst is a Phase 3 expected October 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZEAL biotech catalysts?→
Add ZEAL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zealand Pharma A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.